Thursday, November 01, 2007 2:37:07 AM
How about some Canadian content to help reduce exposure to those sinking US greenbacks? 
not sure if these are biotech values, but they do seem have very low market caps in relation to their potential value if they can translate their research into commercial success.
Amorfix Life Sciences AMF.to (market cap of about $50M Cdn)
from the company website
The company was formed in January 2004 to commercialize the discoveries of the epitope protection (EP) technologies at the University of Toronto discovered by Drs. Neil Cashman and Marty Lehto. These discoveries position the company to become the world authority on aggregated misfolded proteins (AMP) diseases (including Transmissible Spongiform Encephalopathies (TSE), such as Bovine Spongiform Encephalopathy (BSE) and the human form variant Creutzfeldt-Jakob Disease (vCJD), as well as degenerative diseases such as Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS) and Parkinson's Disease (PD). The company will use this new knowledge to develop diagnostic kits, therapeutics and prophylactics for the AMP diseases.
Tekmira (formerly Inex) Pharmaceuticals tkm.to (market cap of about $33M Cdn)
has about 17M in working capital, relatively low burn and agreements with ALNY (granting ALNY worldwide exclusive license to liposomal delivery formulation technology and milestone payments for each product developed using tkm technology together with with tkm access to 3 InterfeRx™ license options from ALNY ) & HANA (licensed marquibo in ph 3 & two other ph I products), plus they have their own product candidates including INX-0167 which in pre-clinical studies demonstrated a strong immune response that translates into a dramatic enhancement in the anti-tumor activity of the monoclonal antibodies Rituxan® or Herceptin®.
Microbix Biosystems Inc.
mbx.to (market cap around $50M Cdn with some recent insider buying (tho small number of shares) by 4 different insiders) - has some interesting looking technology - eg. flu vaccine technology that apparently doubles production capacity using eggs, semen sexing technology for the AI market, and Urokinase for thromobylitc & oncology indications (though i am very much a layman in this regard, but not an egglayer
then there is the more familiar YM Biosciences ymi/ym.to ($75 Cdn Market cap which is approximately currently equal to cash on hand) with Nimotuzumab for Pediatric pontine glioma in Ph 3 trials conducted by Oncoscience AG & several other indications (also run by in-licensing partners) in ph 2) and recently nominating Dr. Philip Frost of imclone/erbitux fame to directorship.
and finally Medicure mph.to/mcu - $120M market cap, with an approved product on the market AGGRASTAT(R) and have pivotal ph 3 trial with 3,000 patient enrolment recently completed for MEND-CABG II for use as a cardioprotectant in patients undergoing CABG surgery. participant in financing has also purchased another 1.2M shares in the open market recently along with a couple of other insiders (who bought much smaller amounts).
anyone familiar with these companies have any thoughts on them? thanks in advance.
not sure if these are biotech values, but they do seem have very low market caps in relation to their potential value if they can translate their research into commercial success.
Amorfix Life Sciences AMF.to (market cap of about $50M Cdn)
from the company website
The company was formed in January 2004 to commercialize the discoveries of the epitope protection (EP) technologies at the University of Toronto discovered by Drs. Neil Cashman and Marty Lehto. These discoveries position the company to become the world authority on aggregated misfolded proteins (AMP) diseases (including Transmissible Spongiform Encephalopathies (TSE), such as Bovine Spongiform Encephalopathy (BSE) and the human form variant Creutzfeldt-Jakob Disease (vCJD), as well as degenerative diseases such as Alzheimer's Disease (AD), Amyotrophic Lateral Sclerosis (ALS) and Parkinson's Disease (PD). The company will use this new knowledge to develop diagnostic kits, therapeutics and prophylactics for the AMP diseases.
Tekmira (formerly Inex) Pharmaceuticals tkm.to (market cap of about $33M Cdn)
has about 17M in working capital, relatively low burn and agreements with ALNY (granting ALNY worldwide exclusive license to liposomal delivery formulation technology and milestone payments for each product developed using tkm technology together with with tkm access to 3 InterfeRx™ license options from ALNY ) & HANA (licensed marquibo in ph 3 & two other ph I products), plus they have their own product candidates including INX-0167 which in pre-clinical studies demonstrated a strong immune response that translates into a dramatic enhancement in the anti-tumor activity of the monoclonal antibodies Rituxan® or Herceptin®.
Microbix Biosystems Inc.
mbx.to (market cap around $50M Cdn with some recent insider buying (tho small number of shares) by 4 different insiders) - has some interesting looking technology - eg. flu vaccine technology that apparently doubles production capacity using eggs, semen sexing technology for the AI market, and Urokinase for thromobylitc & oncology indications (though i am very much a layman in this regard, but not an egglayer
then there is the more familiar YM Biosciences ymi/ym.to ($75 Cdn Market cap which is approximately currently equal to cash on hand) with Nimotuzumab for Pediatric pontine glioma in Ph 3 trials conducted by Oncoscience AG & several other indications (also run by in-licensing partners) in ph 2) and recently nominating Dr. Philip Frost of imclone/erbitux fame to directorship.
and finally Medicure mph.to/mcu - $120M market cap, with an approved product on the market AGGRASTAT(R) and have pivotal ph 3 trial with 3,000 patient enrolment recently completed for MEND-CABG II for use as a cardioprotectant in patients undergoing CABG surgery. participant in financing has also purchased another 1.2M shares in the open market recently along with a couple of other insiders (who bought much smaller amounts).
anyone familiar with these companies have any thoughts on them? thanks in advance.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
